Salim Syed analyst MIZUHO

Currently out of the existing stock ratings of Salim Syed, 103 are a BUY (74.1%), 36 are a HOLD (25.9%).

Salim Syed

Work Performance Price Targets & Ratings Chart

Analyst Salim Syed works at MIZUHO with a stock forecast success ratio of 58.57% fulfilled within 198.85 days on average.

Salim Syed’s has documented 272 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BIIB, Biogen at 22-Feb-2024.

Wall Street Analyst Salim Syed

Analyst best performing recommendations are on NKTX (NKARTA ).
The best stock recommendation documented was for NKTX (NKARTA ) at 11/16/2023. The price target of $9 was fulfilled within 53 days with a profit of $6.64 (281.36%) receiving and performance score of 53.09.

Average potential price target upside

AMGN Amgen ASMB Assembly Biosciences BBIO BridgeBio Pharma BIIB Biogen BMY Bristol-Myers Squibb Company CELG Celgene CYTK Cytokinetics GILD Gilead Sciences NKTX Nkarta  UBX Unity Biotechnology WVE Wave Life Sciences Ltd ATRA Atara Biotherapeutics CHRS Coherus BioSciences CRSP Crispr Therapeutics AG

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

350

$63.7 (22.25%)

258

1 months 20 days ago

1/2 (50%)

$57.44 (19.63%)

325

Buy

329

$42.7 (14.91%)

300

1 months 21 days ago

6/8 (75%)

$35.42 (12.06%)

68

Buy

350

$63.7 (22.25%)

310

1 months 27 days ago

29/30 (96.67%)

$27.96 (8.68%)

508

Hold

314

$27.7 (9.68%)

272

1 months 28 days ago

8/8 (100%)

$2.98 (0.96%)

96

Buy

345

$58.7 (20.50%)

310

2 months 25 days ago

22/23 (95.65%)

$46.64 (15.63%)

610

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Salim Syed is most bullish on?

Potential upside of $60.66 has been obtained for BIIB (BIOGEN)

Which stock is Salim Syed is most reserved on?

Potential downside of -$2.09 has been obtained for NKTX (NKARTA )

What Year was the first public recommendation made by Salim Syed?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?